Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
Clinical trial NCT03781414 · TERMINATED
Trial details
- NCT number
- NCT03781414
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-07
- Primary completion
- 2023-04-20
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.